Another Mega-Deal Despite US Tariff Pressure... Samsung Biologics Secures 1.8 Trillion Won Contract (Comprehensive)

Second Largest Deal in Company History
Another Mega-Scale Order Following This Year’s 2 Trillion Won Contract

Samsung Biologics has demonstrated its competitiveness by securing a large-scale contract with a local company, despite tariff risks originating from the United States.

Samsung Biologics Songdo Campus view. Samsung Biologics

On September 9, Samsung Biologics announced through a public disclosure that it had signed a contract manufacturing organization (CMO) agreement worth 1,294,640,000 dollars (approximately 1.795 trillion won) with a pharmaceutical company based in the United States.

This contract is the second largest in the company's history. It follows the mega-deal signed with a European pharmaceutical company in January, which was worth approximately 2 trillion won. The contract period runs until December 31, 2029, four years from now. The client and product names have not been disclosed due to confidentiality clauses.

With this order, Samsung Biologics has recorded a cumulative order amount of 5.2435 trillion won so far this year. In just eight months, the company has achieved results nearly matching last year's total order amount of 5.4035 trillion won. Since its founding, the company’s cumulative total orders have surpassed 20 billion dollars (about 27.73 trillion won).

In particular, looking at the order trends over the past five years, the growth curve has become steeper each year. Samsung Biologics secured 1.1602 trillion won in orders in 2021, followed by 1.7835 trillion won in 2022, 3.5009 trillion won in 2023, and surpassed 5 trillion won last year. This year’s order amount is expected to easily exceed 6 trillion won. In just five years, the annual order amount has increased nearly sixfold.

Samsung Biologics has continued to secure large-scale contracts even amid increasing management uncertainties across the biopharmaceutical industry, such as the global economic slowdown and tariff impacts. The administration of former U.S. President Donald Trump had announced plans to impose itemized tariffs on imported pharmaceuticals. Despite heightened trade risks, the fact that a U.S.-based pharmaceutical company chose Samsung Biologics is seen as a result of the company’s core competitiveness, which is based on world-class production capacity, quality, and a strong track record of manufacturing performance.

Samsung Biologics Plant 4. Samsung Biologics

Despite concerns that changes in the trade environment, such as U.S. tariff pressures, may require a local production base, Samsung Biologics has remained focused on its domestic production facilities. The company has secured the world’s largest production capacity, totaling 784,000 liters, with all manufacturing plants located in Songdo, Incheon. In April of this year, Plant 5, which incorporates the best practices from Plants 1 to 4 and has a capacity of 180,000 liters, began full-scale operations.

As of September this year, Samsung Biologics has obtained a total of 382 manufacturing approvals from major global regulatory agencies in the United States, Europe, and Japan, demonstrating its quality competitiveness. The number of approvals continues to increase as production capacity expands, and the company maintains an industry-leading regulatory inspection pass rate.

Samsung Biologics plans to accelerate its global market strategy by expanding its key client base from the existing “Top 20” to the “Top 40.” The company has met with various clients at events such as the JP Morgan Healthcare Conference in January, DCAT Week in March, and the BIO International Convention (BIO USA) in June. In July, Samsung Biologics also participated in Interphex Week Tokyo 2025 to showcase its order competitiveness. The company plans to further expand its connections with global and potential clients at upcoming events, including BioJapan 2025 and CPHI Worldwide, both scheduled for October.